Trump administration announces MFN drug pricing deal with Pfizer
The Trump administration announced Pfizer has agreed to provide all of its medicines at Most Favored Nation (MFN) pricing in…
Analyst Comment
Orphan drug landscape in the 7MM: launch patterns, market trends, and HTA insights
ERS 2025: Long-term CFTR use shows clinical benefit but variable microbial impact
ERS 2025: APG808 to address need for biologic for moderate asthma
First responders see AI and other advanced tech as essential
Expanding GLP-1 horizons: Novo Nordisk leads MASH therapeutic race
FDA gives first approval for recurrent respiratory papillomatosis therapy
EASD 2025: Alirocumab significantly reduces ischemic events and mortality in ASCVD
